Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | EVP, General Counsel | August 12, 2026 | August 13, 2026 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,509.254 |
Ending reported balance
After 2026-08-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-12 · Exercise / conversion · Acquired 41,494 · Balance 112,391.254 Row 2 · 2026-08-12 · Exercise / conversion · Acquired 13,433 · Balance 125,824.254 Row 3 · 2026-08-12 · Sale · Disposed 80,315 · Balance 45,509.254 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.0300 to $133.5000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $117.89 · Expires 2033-05-01 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-12 · Exercise / conversion · Disposed 41,494 · Balance 0 F2: The options vested and became exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.71 · Expires 2035-04-28 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-12 · Exercise / conversion · Disposed 13,433 · Balance 0 F3: The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.0300 to $133.5000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The options vested and became exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026.
F3: The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,871 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 31,871 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,433 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · derivative · entry 5 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,433 shares Expires 2035-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,494 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · derivative · entry 4 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,494 shares Expires 2033-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested and became exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 80,315 | $133.46 | $10,718,494.55 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · nonDerivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,509.254 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.0300 to $133.5000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 13,433 | $84.71 | $1,137,909.43 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · nonDerivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,824.254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 41,494 | $117.89 | $4,891,727.66 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,391.254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 46,600 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001737231-26-000002 · primarydocument.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,600 Underlying: Common Stock · 46,600 shares Expires 2036-05-29 F2 · derivative.exercise_date: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 9,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001737231-26-000002 · primarydocument.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,871 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| May 05, 2026 Filed May 7, 2026 16:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 35,312 | $0.00 Strike: $113.15 | $0.00 |
DisclosureSEC source: 0000310158-26-000139 · form4.xml · derivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,312 Underlying: Common Stock · 35,312 shares Expires 2036-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 05, 2026 Filed May 7, 2026 16:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 12,064 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000139 · form4.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,064 Underlying: Common Stock · 12,064 shares Expires 2029-05-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,951 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000086 · form4.xml · derivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,903 Underlying: Common Stock · 2,951 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,454 | $110.03 | $159,983.62 |
DisclosureSEC source: 0000310158-26-000086 · form4.xml · nonDerivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,897.254 Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,951 | $110.03 | $324,698.53 |
DisclosureSEC source: 0000310158-26-000086 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,351.254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,835 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0000310158-26-000046 · form4.xml · derivative · entry 9 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,835 shares Expires 2032-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,792 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0000310158-26-000046 · form4.xml · derivative · entry 8 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,792 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,946 | $0.00 Strike: $75.36 | $0.00 |
DisclosureSEC source: 0000310158-26-000046 · form4.xml · derivative · entry 7 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,946 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 38,835 | $119.15 | $4,627,275.69 |
DisclosureSEC source: 0000310158-26-000046 · form4.xml · nonDerivative · entry 6 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,915.671 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.9600 to $119.5100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 38,835 | $119.15 | $4,627,275.69 |
DisclosureSEC source: 0000310158-26-000046 · form4.xml · nonDerivative · entry 5 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,750.671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.9600 to $119.5100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 56,792 | $119.15 | $6,766,891.74 |
DisclosureSEC source: 0000310158-26-000046 · form4.xml · nonDerivative · entry 4 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,915.671 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.9600 to $119.5100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 56,792 | $119.15 | $6,766,891.74 |
DisclosureSEC source: 0000310158-26-000046 · form4.xml · nonDerivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,707.671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.9600 to $119.5100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 25,946 | $119.15 | $3,091,522.98 |
DisclosureSEC source: 0000310158-26-000046 · form4.xml · nonDerivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,915.671 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.9600 to $119.5100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 25,946 | $119.15 | $3,091,522.98 |
DisclosureSEC source: 0000310158-26-000046 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,861.671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.9600 to $119.5100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 11,583 | $107.40 | $1,244,014.20 |
DisclosureSEC source: 0000310158-26-000028 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,915.671 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:33 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 39,815 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001562180-25-004354 · primarydocument.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,815 Underlying: Common Stock · 39,815 shares Expires 2035-05-30 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:33 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 7,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004354 · primarydocument.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,064 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 40,301 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013037 · form4.xml · derivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,301 Underlying: Common Stock · 40,301 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 8,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013037 · form4.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,854 Underlying: Common Stock · 8,854 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 25,423 | $97.94 | $2,489,928.62 |
DisclosureSEC source: 0001127602-25-002357 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,285.685 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/22. Performance shares were paid out at 169 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2024. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:43 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 24,454 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001562180-24-004656 · primarydocument.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,454 Underlying: Common Stock · 24,454 shares Expires 2034-05-31 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2024 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:43 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004656 · primarydocument.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,296 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2025 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 35,156 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013964 · form4.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,156 Underlying: Common Stock · 35,156 shares Expires 2034-04-29 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| February 02, 2024 Filed Feb 2, 2024 21:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,417 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-24-003093 · form4.xml · derivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,835 Underlying: Common Stock · 19,417 shares Expires 2032-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| February 02, 2024 Filed Feb 2, 2024 21:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 49,499 | $126.97 | $6,284,779.13 |
DisclosureSEC source: 0001127602-24-003093 · form4.xml · nonDerivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,057.76 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.8650 to $127.3000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 02, 2024 Filed Feb 2, 2024 21:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 19,417 | $87.10 | $1,691,220.70 |
DisclosureSEC source: 0001127602-24-003093 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,556.76 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 23,298 | $119.43 | $2,782,480.14 |
DisclosureSEC source: 0001127602-24-002026 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,139.76 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/21. Performance shares were paid out at 161 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2023. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:11 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 17,892 | $0.00 Strike: $19.72 | $0.00 |
DisclosureSEC source: 0001562180-23-004888 · primarydocument.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,892 Underlying: Common Stock · 17,892 shares Expires 2033-06-02 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 2, 2023 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:11 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004888 · primarydocument.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,506 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2024 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 19,141 | $117.59 | $2,250,834.21 |
DisclosureSEC source: 0001127602-23-014759 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,127.593 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.3400 to $117.6800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 41,494 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014537 · form4.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,494 Underlying: Common Stock · 41,494 shares Expires 2033-05-01 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| February 03, 2023 Filed Feb 6, 2023 21:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 75,436 | $0.00 Strike: $56.04 | $0.00 |
DisclosureSEC source: 0001127602-23-003562 · form4.xml · derivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,436 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021. Read SEC document |
| February 03, 2023 Filed Feb 6, 2023 21:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 75,436 | $103.17 | $7,782,762.29 |
DisclosureSEC source: 0001127602-23-003562 · form4.xml · nonDerivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,919.941 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.0200 to $103.5450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 03, 2023 Filed Feb 6, 2023 21:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 75,436 | $56.04 | $4,227,433.44 |
DisclosureSEC source: 0001127602-23-003562 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,355.941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 15,631 | $109.88 | $1,717,534.28 |
DisclosureSEC source: 0001127602-23-002228 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,919.941 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,396 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0001127602-22-024595 · form4.xml · derivative · entry 8 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,792 Underlying: Common Stock · 28,396 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. F4 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 51,884 | $0.00 Strike: $75.36 | $0.00 |
DisclosureSEC source: 0001127602-22-024595 · form4.xml · derivative · entry 7 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,946 Underlying: Common Stock · 51,884 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F4 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 68,367 | $0.00 Strike: $77.62 | $0.00 |
DisclosureSEC source: 0001127602-22-024595 · form4.xml · derivative · entry 6 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,367 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. F4 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 65,487 | $99.85 | $6,538,876.95 |
DisclosureSEC source: 0001127602-22-024595 · form4.xml · nonDerivative · entry 5 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,040.302 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.6100 to $100.3600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 99,768 | $99.07 | $9,884,015.76 |
DisclosureSEC source: 0001127602-22-024595 · form4.xml · nonDerivative · entry 4 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,527.302 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.5500 to $99.4900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 28,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024595 · form4.xml · nonDerivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,295.302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 51,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024595 · form4.xml · nonDerivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,899.302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 68,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024595 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,015.302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.